NCT01324479 is a Phase 1 clinical trial of INC280 in Solid Tumors, sponsored by Novartis Pharmaceuticals.

Who is sponsoring NCT01324479?

NCT01324479 is sponsored by Novartis Pharmaceuticals.

What drugs are being tested in NCT01324479?

Interventions in NCT01324479: INC280.

What condition does NCT01324479 study?

NCT01324479 studies Solid Tumors.

Is NCT01324479 still recruiting?

NCT01324479 is currently completed. Last updated 19 December 2020.

Last reviewed 2020-12-19 · How we verify

NCT01324479

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Study of INC280 in Patients With c-MET Dependent Advanced Solid Tumors

Completed Phase 1 Last updated 19 December 2020

What this trial tests

Phase 1 trial testing INC280 in Solid Tumors in 131 participants. Completed in 4 July 2017.

Timeline

29 February 2012

Primary endpoint
4 July 2017

4 July 2017

Quick facts

Lead sponsor	Novartis Pharmaceuticals
Phase	Phase 1
Status	Completed
Study type	INTERVENTIONAL
Allocation	na
Design	single group
Masking	none
Primary purpose	treatment
Enrollment	131
Start date	29 February 2012
Primary completion	4 July 2017
Estimated completion	4 July 2017
Sites	47 locations across France, Hong Kong, Italy, Netherlands, Taiwan, Germany, Israel, Norway

Drugs / interventions tested

INC280 — full drug profile →

Conditions studied

Solid Tumors — all drugs for Solid Tumors →

Sponsor

Novartis Pharmaceuticals — full company profile →

Who can join

18 and older, any sex, with Solid Tumors. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This study will assess the safety and efficacy of INC280 in patients with solid tumors that are refractory to current treatment or for which there is not a current standard of care and whose tumors have dysregulation of the c-MET pathway.

Publications & conference data

8 peer-reviewed publications reference this trial (live from Europe PMC):

Clinical update on head and neck cancer: molecular biology and ongoing challenges.
Alsahafi E, Begg K, Amelio I, Raulf N, et al · · 2019 · cited 380× · PMID 31308358 · DOI 10.1038/s41419-019-1769-9
Molecular mechanism(s) of regulation(s) of c-MET/HGF signaling in head and neck cancer.
Raj S, Kesari KK, Kumar A, Rathi B, et al · · 2022 · cited 111× · PMID 35081970 · DOI 10.1186/s12943-022-01503-1
MET Oncogene in Non-Small Cell Lung Cancer: Mechanism of MET Dysregulation and Agents Targeting the HGF/c-Met Axis.
Liang H, Wang M. · · 2020 · cited 89× · PMID 32273721 · DOI 10.2147/ott.s231257
Volitinib, a potent and highly selective c-Met inhibitor, effectively blocks c-Met signaling and growth in c-MET amplified gastric cancer patient-derived tumor xenograft models.
Gavine PR, Ren Y, Han L, Lv J, et al · · 2015 · cited 87× · PMID 25248999 · DOI 10.1016/j.molonc.2014.08.015
Molecular correlates of response to capmatinib in advanced non-small-cell lung cancer: clinical and biomarker results from a phase I trial.
Schuler M, Berardi R, Lim WT, de Jonge M, et al · · 2020 · cited 75× · PMID 32240796 · DOI 10.1016/j.annonc.2020.03.293
Emerging therapeutic agents for lung cancer.
Dholaria B, Hammond W, Shreders A, Lou Y. · · 2016 · cited 66× · PMID 27938382 · DOI 10.1186/s13045-016-0365-z
Activated HGF-c-Met Axis in Head and Neck Cancer.
Arnold L, Enders J, Thomas SM. · · 2017 · cited 53× · PMID 29231907 · DOI 10.3390/cancers9120169
Targeting the HGF-cMET Axis in Hepatocellular Carcinoma.
Venepalli NK, Goff L. · · 2013 · cited 52× · PMID 23606971 · DOI 10.1155/2013/341636

Verify or expand the search:

Other trials of INC280

Trials testing the same drug.

NCT03484923 — Study of Efficacy and Safety of Novel Spartalizumab Combinations in Patients With Previously Treated Unresectable or Met · Phase 2 · completed
NCT03240393 — Study of Oral cMET Inhibitor INC280 in Chinese Patients With EGFR Wild-type Advanced Non-small Cell Lung Cancer (NSCLC) · Phase 2 · withdrawn
NCT03333343 — Study of EGF816 in Combination With Selected Targeted Agents in EGFR-mutant NSCLC · Phase 1 · active not recruiting
NCT02925104 — A Dose Escalation Study to Assess PK, Safety and Tolerability of INC280 When Taken With Food in cMET Dysregulated Advanc · Phase 1 · completed
NCT02520752 — A DDI Study to Assess the Effect of INC280 on the PK of Midazolam and Caffeine in Patients With cMET-dysregulated Advanc · Phase 1 · completed

Other recruiting trials for Solid Tumors

Currently open trials in the same condition.

NCT07529002 — Clinical Application of 89Zr-s-C1 PET/CT Imaging in Solid Tumors · recruiting
NCT07416123 — A Study of GEN1106 in Participants With Solid Tumors · Phase 1 · recruiting
NCT07522073 — A Study to Evaluate Chemotherapy With or Without INCB161734 in Previously Untreated, KRAS G12D-Mutated Metastatic Pancre · Phase 3 · recruiting
NCT07395258 — A Study to Test Different Doses of BI 3923948 Alone and in Combination With an Anti-PD-1 Antibody in People With Differe · Phase 1 · recruiting
NCT07505069 — Exploring the Clinical Value of RT01-89Zr PET Imaging in Solid Tumors · EARLY_PHASE1 · recruiting

Other Novartis Pharmaceuticals trials

Trials by the same sponsor.

NCT07498335 — Study to Assess the Efficacy, Pharmacokinetics, Safety and Tolerability of Atrasentan in Pediatric Patients With Primary · Phase 3 · not yet recruiting
NCT07489573 — Study of Efficacy and Safety of Secukinumab in Chinese Adult Patients With Moderate to Severe Hidradenitis Suppurativa · Phase 4 · not yet recruiting
NCT07484269 — PULSE Registry: for Patients Receiving Lutetium (177Lu) Vipivotide Tetraxetan · not yet recruiting
NCT07416162 — A Study of Iptacopan in Korean Patients With Paroxysmal Nocturnal Hemoglobinuria or C3 Glomerulopathy · not yet recruiting
NCT07387926 — Safety and Efficacy of Asciminib in Pediatrics and Young Adults With Relapse/Refractory (r/r) Philadelphia Positive (Ph+ · Phase 1, PHASE2 · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT01324479 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Novartis Pharmaceuticals
Last refreshed: 19 December 2020

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT01324479.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing